Kisspeptin
Also known as Kisspeptin-10 · Kp-10 · Kisspeptin-54
Upstream regulator of reproductive axis (GnRH/LH/FSH). FDA-flagged for compounding concerns.
FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
Evidence visual
Kisspeptin evidence and risk matrix
advanced researcher fit
Evidence
Tier B
Risk
medium
Regulatory
not approved
WADA
S2
FDA
flagged
Route
intravenous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Kisspeptin is an upstream regulator of the reproductive axis, stimulating GnRH neurons to drive LH/FSH release. Human volunteer studies include IV bolus dosing with kisspeptin-10 showing LH peak within ~45 minutes, maximal stimulation at ~1 µg/kg. FDA flagged kisspeptin-10 for compounding safety with limited safety data and immunogenicity concerns. WADA lists it as a peptide hormone.
Decision path
Where Kisspeptin fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Kisspeptin belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Upstream regulator of reproductive axis via stimulation of GnRH neurons, driving LH/FSH release.
intravenous, subcutaneous
Human: IV bolus with maximal LH stimulation at ~1 µg/kg (Kp-10).
LH/FSH axis stimulation; fertility research applications.
Acute LH response within ~45 minutes; fertility endpoints context-specific.
No formal label; high endocrine interaction potential.
FDA: limited safety data, immunogenicity concerns for compounding.
High endocrine interaction potential with GnRH analogues and gonadotropins. Do not provide stacking guidance.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
HPG-axis signaling overlap; FDA flags kisspeptin-10 compounding uncertainty.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Kisspeptin.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.